Receive up-to-the-minute news updates on the hottest topics with NewsHub. Install now.

Search results

11-20 results from 26 for query «psoriasis»

4 May, 2015 8:21 AM Glenmark up 2.5% on tentative USFDA nod for psoriasis cream

Shares of Glenmark Pharma climbed 2.55 percent intraday Monday on getting tentative approval from the US health regulator for generic Calcipotriene cream. Glenmark Pharmaceuticals Inc, USA, a subsidiary of the company, has been granted tentative approval by the United States Food and Drug Administration (USFDA) for Calcipotriene cream, 0.005 percent 27

22 April, 2015 12:08 AM Healers from nature’s lap

The modern hermetically sealed lifestyle is turning many vulnerable to diseases. The sublime healing qualities of nature have become alien to the present-day generation due to lack of awareness of traditional healing techniques and absence of serious attempts at validation of ingenious medicines. ‘Kaananasangamom,’ the tribal festival currently on at the Kanakakkunnu 17

8 April, 2015 9:56 AM Dr Reddy's at new high, files 3 NDAs with US drug regulator

Shares of Dr Reddy's Laboratories touched a record high of Rs 3,768 on Wednesday, up 2.4 percent intraday after the drug major and its subsidiary Promius Pharma filed three new drug applications with the US Food and Drug Administration (USFDA). "The three NDAs - DFD-01, DFD-09, DFN-11 are focussed on developing and commercialising therapies in dermatology 54

8 April, 2015 3:33 AM Dr. Reddy’s Laboratories and Its Subsidiary Promius PharmaTM Announce the Filing of Three NDAs With the USFDA

Dr. Reddy's Laboratories (RDY) and its subsidiary, Promius Pharma™, LLC today announced the filing of three 505(b)(2) New Drug Applications (NDAs) with the U.S. Food and Drug Administration (US FDA). The three NDAs - DFD-01, DFD-09, and DFN-11, are in support of Dr. Reddy’s Proprietary Products group, focused on developing and commercializing therapies 38

8 April, 2015 2:49 AM Dr Reddy's files three new drug applications with USFDA

Drug major Dr Reddy's Laboratories on Tuesday said it has filed three new drug applications (NDAs), aimed to be used in the treatments of psoriasis, rosacea, migraine, with the US health regulator. The Hyderabad-based firm and its subsidiary, Promius Pharma LLC have filed three new drug applications with the US Food and Drug Administration (USFDA) 70

7 April, 2015 3:27 PM Dr Reddy's files new drug application with USFDA

Dr Reddy's Laboratories and its subsidiary, Promius Pharma today announced filing of three new drug applications (NDAs) with the US Food and Drug Administration. Of the three, two are related to dermatology (skincare) applications and one is a corticosteroid, the company said in a filing to the BSE today. Raghav Chari, Executive Vice President of Proprietary 22

25 March, 2015 7:52 AM Looking to increase R&D spend in excess of $300 mn: Sun

Sun Pharmaceutical Wednesday began the integration of Ranbaxy ’s business following the successful closure of its merger. The integration, planned by Sun Pharma over many months, will focus on supporting strong growth, the company said. Addressing the media, Israel Makov, Chairman, Sun Pharma, said: “The combined entity will capitalize on the expanded 127

9 December, 2014 6:04 AM Drug for skin disorder may help in treating Alzheimer’s: Scientists

It may be possible to treat Alzheimer’s disease with a drug used for treating a skin disorder, German researchers have found, according to an announcement by the Johannes Gutenberg University of Mainz, Monday. A drug, approved for treating the dermal disorder psoriasis, stimulates the activity of the enzyme ADAM10 in the brain of Alzheimer’s patients 50

1 December, 2014 10:50 AM Ranbaxy launches arthritis drug Infimab in India

Ranbaxy Laboratories today launched the first biosimilar version of Johnson and Johnson's Remicade, a drug used for treating various conditions including rheumatoid arthritis. Infimab has been introduced in the Indian market through a licensing partnership with Epirus Biopharmaceuticals, Ranbaxy said in a statement. Infimab will be manufactured by Reliance 3

14 November, 2014 1:47 PM Sun, Merck to dissolve branded generics JV?

While the work had started by drawing up a list of initial drugs that would be developed and marketed, sources say the progress did not happen beyond the list being formed. In 3 years, not a single drug has come out of this joint venture. The other reason, we learn, is that the priorities for both Sun Pharma and Merck have changed in these last 3 years 4